Literature DB >> 26688602

Implication of vaccination on measles reduction and elimination in Nigeria.

A B Onoja1, K M Hamid2, J A Adeniji3, M D Mukhtar4.   

Abstract

BACKGROUND: The availability of a safe and effective vaccine has encouraged the establishment of measles mortality reduction and elimination goals in six World Health Organization regions. In the WHO-AFRO region, they intend to eliminate measles by 2020. This initiative led to the successful elimination of measles in 2012 in the American region. This study mined data from independent investigations in two geographical regions in Nigeria in order to observe the prospects of preventive measures against wild measles virus in a resource limited setting.
MATERIALS AND METHODS: Retrospective data from 757 children between the ages of 10 months and 13years were used. 500 were from children in Kano, Northwest Nigeria and 257 from children in Ibadan, Southwest Nigeria. Data analysis was done using SPSS 16.0.
RESULTS: In all, 386 (75.4%) of the vaccinated children were protected while 121 (23.6%) were not protected. In the unvaccinated children, 63 (25.7%) were protected while 135 (55.1%) were not protected (X2=120.919, p=0.000). In Kano, 81 % of the vaccinated children were protected while 18.4% were not protected. In Ibadan, 95% of the vaccinated were protected (X2=22.129, p = 0.000).
CONCLUSION: The herd immunity in both Kano and Ibadan is good enough to reduce wild measles virus infection. This finding is encouraging because Kano has suffered several epidemics prior to the vaccination campaigns resulting from religious apathy which is the bane of vaccination efforts. Here is evidence that with the right approach in Northern Nigeria, it is possible to sustain national and global immunization drive.

Entities:  

Keywords:  developing country; immunization; measles; vaccination

Year:  2014        PMID: 26688602      PMCID: PMC4682907     

Source DB:  PubMed          Journal:  Afr J Med Med Sci        ISSN: 0309-3913


  17 in total

1.  Measles epidemic sweeps through Afghanistan.

Authors:  K Ahmad
Journal:  Lancet       Date:  2000-04-22       Impact factor: 79.321

2.  MORBILLI IN SYDNEY: A REVIEW OF 3601 CASES WITH CONSIDERATION OF MORBIDITY, MORTALITY AND MEASLES ENCEPHALOMYELITIS.

Authors:  C R BOUGHTON
Journal:  Med J Aust       Date:  1964-11-28       Impact factor: 7.738

Review 3.  The clinical significance of measles: a review.

Authors:  Robert T Perry; Neal A Halsey
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

4.  The concept of herd immunity and the design of community-based immunization programmes.

Authors:  R M Anderson
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

5.  Measles imported by returning U.S. travelers aged 6-23 months, 2001-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-04-08       Impact factor: 17.586

6.  Malnutrition, measles, mortality, and the humanitarian response during a famine in Ehiopia.

Authors:  P Salama; F Assefa; L Talley; P Spiegel; A van Der Veen; C A Gotway
Journal:  JAMA       Date:  2001-08-01       Impact factor: 56.272

7.  Identification of measles virus-specific hemolysis-inihibiting antibodies separate from hemagglutination-inhibiting antibodies.

Authors:  E Norrby; Y Gollmar
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

8.  Childhood survival in Haiti: protective effect of measles vaccination.

Authors:  E A Holt; R Boulos; N A Halsey; L M Boulos; C Boulos
Journal:  Pediatrics       Date:  1990-02       Impact factor: 7.124

9.  Identification of paramyxovirus-specific haemolysis-inhibiting antibodies separate from haemagglutinating-inhibiting and neuraminidase-inhibiting antibodies. 1. Sendai virus haemolysis-inhibiting antibodies.

Authors:  C Orvell
Journal:  Acta Pathol Microbiol Scand B       Date:  1976-12

10.  What led to the Nigerian boycott of the polio vaccination campaign?

Authors:  Ayodele Samuel Jegede
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.